Trinity Biotech (TRIB) Competitors $1.27 -0.01 (-0.78%) (As of 09/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends TRIB vs. MAAQ, IMMX, RPHM, RLYB, ZIVO, AADI, PASG, LVTX, DRRX, and VTVTShould you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include Mana Capital Acquisition (MAAQ), Immix Biopharma (IMMX), Reneo Pharmaceuticals (RPHM), Rallybio (RLYB), ZIVO Bioscience (ZIVO), Aadi Bioscience (AADI), Passage Bio (PASG), LAVA Therapeutics (LVTX), DURECT (DRRX), and vTv Therapeutics (VTVT). These companies are all part of the "pharmaceutical products" industry. Trinity Biotech vs. Mana Capital Acquisition Immix Biopharma Reneo Pharmaceuticals Rallybio ZIVO Bioscience Aadi Bioscience Passage Bio LAVA Therapeutics DURECT vTv Therapeutics Trinity Biotech (NASDAQ:TRIB) and Mana Capital Acquisition (NASDAQ:MAAQ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership. Is TRIB or MAAQ more profitable? Mana Capital Acquisition has a net margin of 0.00% compared to Trinity Biotech's net margin of -38.02%. Company Net Margins Return on Equity Return on Assets Trinity Biotech-38.02% N/A -26.62% Mana Capital Acquisition N/A N/A N/A Does the media prefer TRIB or MAAQ? In the previous week, Trinity Biotech had 1 more articles in the media than Mana Capital Acquisition. MarketBeat recorded 1 mentions for Trinity Biotech and 0 mentions for Mana Capital Acquisition. Mana Capital Acquisition's average media sentiment score of 0.00 beat Trinity Biotech's score of -0.03 indicating that Mana Capital Acquisition is being referred to more favorably in the news media. Company Overall Sentiment Trinity Biotech Neutral Mana Capital Acquisition Neutral Do institutionals and insiders believe in TRIB or MAAQ? 79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 68.4% of Mana Capital Acquisition shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in TRIB or MAAQ? Trinity Biotech received 334 more outperform votes than Mana Capital Acquisition when rated by MarketBeat users. However, 100.00% of users gave Mana Capital Acquisition an outperform vote while only 72.04% of users gave Trinity Biotech an outperform vote. CompanyUnderperformOutperformTrinity BiotechOutperform Votes33572.04% Underperform Votes13027.96% Mana Capital AcquisitionOutperform Votes1100.00% Underperform VotesNo Votes Which has better earnings and valuation, TRIB or MAAQ? Mana Capital Acquisition has lower revenue, but higher earnings than Trinity Biotech. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrinity Biotech$56.83M0.16-$24.02M-$2.79-0.44Mana Capital AcquisitionN/AN/AN/AN/AN/A Do analysts prefer TRIB or MAAQ? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AMana Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A SummaryTrinity Biotech beats Mana Capital Acquisition on 5 of the 9 factors compared between the two stocks. Ad Unstoppable ProsperityMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a row! But – knowing what the options trading landscape looks like, and what you're up against is a must.So make sure you claim your free seat by clicking here now. Get Trinity Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TRIB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat are MarkeBeat Followers?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRIB vs. The Competition Export to ExcelMetricTrinity BiotechDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.37M$3.11B$5.49B$8.41BDividend YieldN/A0.72%4.97%4.06%P/E Ratio-0.44151.64146.4418.90Price / Sales0.1635.811,700.5287.10Price / CashN/A17.0237.2531.49Price / Book-0.393.644.944.54Net Income-$24.02M$29.98M$115.07M$225.08M7 Day Performance-23.13%-2.35%8.68%3.26%1 Month Performance-47.66%-8.44%15.09%7.69%1 Year Performance-64.35%-8.78%32.84%14.55% Trinity Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MAAQMana Capital Acquisition0 of 5 stars0.00 / 5 stars$0.28+3.7%N/A-39.6%$48.67MN/A0.001Gap UpHigh Trading VolumeIMMXImmix Biopharma4.0345 of 5 stars4.03 / 5 stars$1.81-2.2%$7.00+286.7%-46.2%$47.81MN/A-1.959News CoverageRPHMReneo Pharmaceuticals3.212 of 5 stars3.21 / 5 stars$1.39+1.5%$11.01+692.3%-79.4%$46.47MN/A-0.6430News CoverageRLYBRallybio3.1785 of 5 stars3.18 / 5 stars$1.10flat$10.00+809.1%-76.6%$45.64MN/A-0.5940News CoverageZIVOZIVO Bioscience0 of 5 stars0.00 / 5 stars$13.50+3.8%N/A+60.7%$45.38M$30,000.00-3.5510Gap DownAADIAadi Bioscience3.8486 of 5 stars3.85 / 5 stars$1.84-2.1%$10.25+457.1%-66.0%$45.18M$23.82M-0.7240Short Interest ↑PASGPassage Bio3.0975 of 5 stars3.10 / 5 stars$0.73flat$8.33+1,045.9%-1.8%$44.83MN/A-0.48130News CoverageGap UpLVTXLAVA Therapeutics2.4546 of 5 stars2.45 / 5 stars$1.76+2.3%$6.00+240.9%-1.2%$44.62M$7.40M-1.6360Positive NewsDRRXDURECT2.9722 of 5 stars2.97 / 5 stars$1.42-9.0%$21.00+1,378.9%-53.7%$44.08M$8.41M-1.4980VTVTvTv Therapeutics0 of 5 stars0.00 / 5 stars$15.14+6.2%N/A-20.2%$42.93M$2.02M-1.719Positive NewsGap DownHigh Trading Volume Related Companies and Tools Related Companies: Mana Capital Acquisition Competitors Immix Biopharma Competitors Reneo Pharmaceuticals Competitors Rallybio Competitors ZIVO Bioscience Competitors Aadi Bioscience Competitors Passage Bio Competitors LAVA Therapeutics Competitors DURECT Competitors vTv Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRIB) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trinity Biotech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Trinity Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
